4//SEC Filing
Daigneault Alessandra 4
Accession 0000950142-21-003504
CIK 0001719406other
Filed
Nov 1, 8:00 PM ET
Accepted
Nov 2, 4:05 PM ET
Size
24.8 KB
Accession
0000950142-21-003504
Insider Transaction Report
Form 4
Daigneault Alessandra
General Counsel & Secretary
Transactions
- Conversion
Employee Stock Option (Right to buy)
2021-09-02$3.07/sh−28,916$88,772→ 71,924 totalExercise: $3.07Exp: 2030-09-01→ Common Stock (28,916 underlying) - Exercise/Conversion
Common Stock
2021-08-19$3.07/sh+27,395$84,103→ 33,715 total - Award
Restricted Stock Units
2021-09-02+10,496→ 26,101 total→ Common Stock (10,496 underlying) - Conversion
Employee Stock Option (Right to buy)
2021-08-19$3.07/sh−43,000$132,010→ 100,840 totalExercise: $3.07Exp: 2030-09-01→ Common Stock (43,000 underlying) - Award
Restricted Stock Units
2021-08-19+15,605→ 15,605 total→ Common Stock (15,605 underlying) - Award
Restricted Stock Units
2021-09-02+7,502→ 33,603 total→ Common Stock (7,502 underlying) - Sale
Common Stock
2021-08-23$13.11/sh−33,715$442,004→ 0 total - Exercise/Conversion
Common Stock
2021-09-02$3.07/sh+18,420$56,549→ 18,420 total - Conversion
Employee Stock Option (Right to buy)
2021-09-02$3.07/sh−20,666$63,445→ 28,934 totalExercise: $3.07Exp: 2030-11-15→ Common Stock (20,666 underlying) - Exercise/Conversion
Common Stock
2021-09-02$3.07/sh+13,164$40,413→ 31,584 total
Footnotes (5)
- [F1]Shares and restricted stock units acquired pursuant to the exercise of 43,000 vested stock options under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan (the "Plan"). The Reporting person received 27,395 freely tradable shares of common stock, par value $0.001 per share, of NRX Pharmaceuticals, Inc. (the "Common Stock ") and 15,605 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock. These restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022.
- [F2]Shares and restricted stock units acquired pursuant to the exercise of 28,916 vested stock options under the Plan. The Reporting person received 18,420 freely tradable shares of Common Stock and 10,496 restricted stock units under the Plan, each restricted stock unit representing a right to receive one share of Common Stock. These restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022.
- [F3]Shares and restricted stock units acquired pursuant to the exercise of 20,666 vested stock options under the Plan. The Reporting person received 13,164 freely tradable shares of Common Stock and 7,502 restricted stock units under the Plan, each restricted stock unit representing a right to receive one share of Common Stock. These restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022.
- [F4]From an option grant dated September 1, 2020; subject to certain conditions, the options will generally vest in 24 equal installments every month commencing on 09/30/2020 and fully vesting on 09/30/2022. As of September 1, 2021, 22,923 options had vested and were available for exercise.
- [F5]From an option grant dated November 15, 2020; subject to certain conditions, the options will generally vest at a rate of 2066 every month commencing on 11/30/2020 through 10/30/1022 and the final 2,082 shares on 11/30/2022. As of September 1, 2021, 20,666 shares had vested and were available for exercise.
Documents
Issuer
NRX Pharmaceuticals, Inc.
CIK 0001719406
Entity typeother
Related Parties
1- filerCIK 0001864648
Filing Metadata
- Form type
- 4
- Filed
- Nov 1, 8:00 PM ET
- Accepted
- Nov 2, 4:05 PM ET
- Size
- 24.8 KB